Reuters logo
BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79
November 9, 2017 / 12:51 PM / a month ago

BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79

Nov 9 (Reuters) - Nabriva Therapeutics Plc

* Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights

* Q3 loss per share $0.79

* Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S

* Nabriva - On track to complete patient enrollment for second phase 3 trial, leap 2, before year end 2017, & expects topline results in spring 2018​

* Nabriva Therapeutics Plc - ‍$112.7 million cash and investments as of September 30, 2017​

* Nabriva Therapeutics Plc - ‍Cash balance is expected to fund operations into Q4 of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below